BI 1584862 clinical trials
Also written BI 1584862.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses BI 1584862 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 1584862
- 6
Studies by the year they started
6 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test BI 1584862.
- Dec 2026A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyPhase 2 · Boehringer Ingelheim
Studies
Open first, then newest update. How each study uses BI 1584862 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyActive, not recruitingPhase 2Boehringer IngelheimNCT06769048Written as BI 1584862
- A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver ProblemsCompletedPhase 1Boehringer IngelheimNCT06957756Written as BI 1584862
- A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the BloodCompletedPhase 1Boehringer IngelheimNCT06041438Written as BI 1584862
- A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are ToleratedCompletedPhase 1Boehringer IngelheimNCT06148948Written as BI 1584862
- A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy MenCompletedPhase 1Boehringer IngelheimNCT06006598Written as BI 1584862
- A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without FoodCompletedPhase 1Boehringer IngelheimNCT05520827Written as BI 1584862